1352066-68-2

Usage

Uses

AMG-232 is a potent MDM2-P53 inhibitor for use as an anti-tumor agent.

Biological Activity

amg-232 is a novel inhibitor of p53-mdm2 with ic50 value of 9.2 nm [1].tumor protein p53 (p53) is a very unstable protein with a half-life ranging from 5 to 30 min and participates in a variety of anticancer processes, such as inducing cell apoptosis and inhibiting angiogenesis. mouse double minute 2 homolog (mdm2), also named as e3 ubiquitin-protein ligase mdm2, involves in mediating p53 tumor suppressor. it has been conclusively demonstrated p53 is under-expressed in tumor cells [2].amg-232 is a potent p53-mdm2 interaction inhibitor and is regarded as a promising drug in clinic. when tested with sjsa-1 tumor cell line, amg-232 treatment resulted in cell-cycle arrest and inhibition of tumor cell proliferation via binding to mdm2 protein and robustly inducing p53 activity. it was shown that p53-mdm2 bond rang from a kd of 60 to 700 nm depending on the length of p53 peptide [3].in mouse model with sjsa-1 tumor cells subcutaneous xenograft, co-administration of amg-232 and chemotherapies induced dna damage and p53 activity which resulted in significantly superior antitumor efficacy and regression through arresting cell growth and inducting apoptosis [3].

references

[1]. rew, y., et al., discovery of am-7209, a potent and selective 4-amidobenzoic acid inhibitor of the mdm2-p53 interaction. j med chem, 2014. 57(24): p. 10499-511.[2]. moll, u.m. and o. petrenko, the mdm2-p53 interaction. mol cancer res, 2003. 1(14): p. 1001-8.[3]. canon, j., et al., the mdm2 inhibitor amg 232 demonstrates robust antitumor efficacy and potentiates the activity of p53-inducing cytotoxic agents. mol cancer ther, 2015. 14(3): p. 649-58.

Upstream product

• 2026-48-4 (S)-valinol 
• 1126-46-1 Methyl 4-chlorobenzoate 
• 1352073-02-9 methyl 4-(3-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-5-oxopentanoate 
• 68968-12-7 2-(3-chlorophenyl)-1-(4-chlorophenyl)ethan-1-one 
• 1878-65-5 3-chlorophenylacetic acid 
• 108-90-7 chlorobenzene 

Relevant academic research and scientific papers

Development of a Commercial Process to Prepare AMG 232 Using a Green Ozonolysis-Pinnick Tandem Transformation

A robust process to manufacture AMG 232 was developed to deliver drug substance of high purity. Highlights of the commercial process development efforts include the following: (i) use of a novel bench-stable Vilsmeier reagent, methoxymethylene-N,N-dimethyliminium methyl sulfate, for selective in situ activation of a primary alcohol intermediate; (ii) use of a new crystalline and stable isopropyl calcium sulfinate reagent ensuring robust preparation of a sulfone intermediate; (iii) development of a safe ozonolysis process conducted in an aqueous solvent mixture in either batch or continuous manufacturing mode; and (iv) control of the drug substance purity by crystallization of a salt rejecting impurities effectively. The new process was demonstrated to afford the drug substance (99.9 LC area %) in 49.8% overall yield from starting material DLAC (1).

PROCESSES FOR PREPARING A MDM2 INHIBITOR

The present invention provides commercial processes for preparing 2- ((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-l-((S)-l-(isopropylsulfonyl)-3-methylbutan-2-yl)-3 -m ethyl-2-oxopiperi din-3 -yl)acetic acid as well as intermediates thereof.

MDM2 inhibitor as well as preparation method, pharmaceutical composition and application thereof

The invention provides an MDM2 inhibitor as well as a preparation method, a pharmaceutical composition and an application thereof. Specifically, the invention provides the compound represented by a formula I, wherein the groups are defined in the specific

COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS

The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain

PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR

The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.

Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer

We recently reported the discovery of AMG 232 (1), a potent and selective piperidinone inhibitor of the MDM2-p53 protein-protein interaction. Compound 1 is currently being evaluated in human clinical trials for the treatment of cancer. This article provides an overview of its discovery from the de novo design of the piperidinone series to the structure-activity studies leading to the identification of 1. In addition, this article also describes the preclinical pharmacology and pharmacokinetics of 1, along with its drug metabolism and safety assessment.

Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development

We recently reported the discovery of AM-8553 (1), a potent and selective piperidinone inhibitor of the MDM2-p53 interaction. Continued research investigation of the N-alkyl substituent of this series, focused in particular on a previously underutilized interaction in a shallow cleft on the MDM2 surface, led to the discovery of a one-carbon tethered sulfone which gave rise to substantial improvements in biochemical and cellular potency. Further investigation produced AMG 232 (2), which is currently being evaluated in human clinical trials for the treatment of cancer. Compound 2 is an extremely potent MDM2 inhibitor (SPR KD = 0.045 nM, SJSA-1 EdU IC50 = 9.1 nM), with remarkable pharmacokinetic properties and in vivo antitumor activity in the SJSA-1 osteosarcoma xenograft model (ED50 = 9.1 mg/kg).

PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER

The present invention provides MDM2 inhibitor compounds of Formula (I), wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.